Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales

The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol

(2021) Yasaman Taheri et al.   Frontiers in Pharmacology

New Perspectives on Antimicrobial Agents: Cefiderocol

(2021) Erin K. McCreary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA

(2021) Sabrina Klein et al.   CLINICAL INFECTIOUS DISEASES

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients

(2020) Kenneth V.I. Rolston et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units

(2020) Alyssa R. Golden et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Structural basis of reduced susceptibility to ceftazidime–avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion

(2020) Akito Kawai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime

(2020) Ryan K Shields et al.   CLINICAL INFECTIOUS DISEASES

Species Identification and Antibiotic Resistance Prediction by Analysis of Whole Genome Sequence Data Using ARESdb – An Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial

(2020) Ines Ferreira et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-negative Bacilli: A Comparison of Disk Diffusion to Broth Microdilution

(2020) C. Paul Morris et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)

(2020) Naoki Kohira et al.   Journal of Global Antimicrobial Resistance

Pharmacokinetics-pharmacodynamics of β-lactamase inhibitors: are we missing the target?

(2019) Marguerite L Monogue et al.   Expert Review of Anti-Infective Therapy

Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin

(2019) Takafumi Sato et al.   CLINICAL INFECTIOUS DISEASES

The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics

(2019) Malcom G P Page   CLINICAL INFECTIOUS DISEASES

In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria

(2019) Yoshinori Yamano   CLINICAL INFECTIOUS DISEASES

Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model

(2018) Islam M. Ghazi et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa

(2018) Islam M. Ghazi et al.   PHARMACOLOGY

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015

(2018) James A. Karlowsky et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

(2018) Krystyna M. Kazmierczak et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens

(2017) J. Dobias et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Risk Factors for Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Carriage Upon Pediatric Intensive Care Unit Admission

(2017) David X. Li et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals

(2017) Matthew E. Falagas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace

(2017) Latania K. Logan et al.   JOURNAL OF INFECTIOUS DISEASES

Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-ResistantEnterobacteriaceaeBacteremia

(2016) Pranita D. Tamma et al.   CLINICAL INFECTIOUS DISEASES

The Role of Epidemic Resistance Plasmids and International High-Risk Clones in the Spread of Multidrug-Resistant Enterobacteriaceae

(2015) Amy J. Mathers et al.   CLINICAL MICROBIOLOGY REVIEWS

Resistance to Colistin Associated with a Single Amino Acid Change in Protein PmrB among Klebsiella pneumoniae Isolates of Worldwide Origin

(2014) Aurélie Jayol et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Aminoglycoside modifying enzymes

(2010) Maria S. Ramirez et al.   DRUG RESISTANCE UPDATES

Evaluation of CHROMagar KPC for Rapid Detection of Carbapenem-Resistant Enterobacteriaceae

(2008) Z. Samra et al.   JOURNAL OF CLINICAL MICROBIOLOGY